Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

The new agreement comes at a time when GSK and CureVac have been at risk of falling behind in mRNA vaccines for respiratory diseases, with combined flu/COVID-19 candidates from Moderna and Pfizer ...

GSK said at an R&D update in the summer that it expects to have two mRNA candidates in clinical trials within 12 months and six within the next four years, including seasonal flu shots.

Moderna, Pfizer, and a partnership between GSK and CureVac are reportedly working ... and Prevention reported the first death from bird flu on Monday, announcing an elderly patient with underlying ...

British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on a cancer vaccine research program.

GSK) today announced it has started shipping doses of its trivalent influenza vaccines to US healthcare providers and pharmacies in preparation for the 2024-25 flu season. This immediately follows ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...